Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Innovative e-Health CARDIO SLEEP DASHBOARD provides timely insights into patients’ sleep status and compliance with sleep apnea therapy specially design for cardiologists needs
CAESAREA, Israel, May 07, 2018 -- Itamar Medical Ltd. (TASE:ITMR), an industry leading company that develops, manufactures, and markets sleep apnea management solutions with focus on the cardiology market, today announced the launch of SleePath, the first integrated e-health sleep apnea care pathway monitoring system that allows cardiologists to monitor patients with atrial fibrillation (AF) sleep apnea management status and compliance with continuous positive airway pressure (CPAP) devices on demand.1 Effective management of sleep apnea is essential for improving outcomes in patients with AF, a type of irregular heartbeat that affects 6 million individuals in the United States. SleePath will be unveiled at Heart Rhythm 2018, the annual meeting of the Heart Rhythm Society, which is taking place in Boston, May 9 – 12.
Sleep apnea occurs in roughly 50% of patients with AF and is found in a higher proportion of AF patients scheduled for catheter ablation, a minimally invasive procedure commonly used to treat AF, which eliminates the cells that give rise to irregular heartbeat. In AF patients with sleep apnea, catheter ablation is most effective when used in conjunction with adherence to a CPAP regimen.
“Effective management of Sleep Apnea is now believed to be critical for controlling atrial fibrillation post ablation. The ability for us, the electrophysiologists, to assess patients’ sleep apnea status and their adherence to CPAP on demand and correlating it to the AF manifestations is a big help,” said Dr. Elad Anter, of Beth Israel Deconess in Boston. “The information that SleePath provides is important for achieving optimal outcomes following catheter ablation. Knowing that a patient isn’t using their CPAP as prescribed is an important first step in opening a dialog with the sleep experts that can identify obstacles and help improve adherence.”
Utilizing data from one of the leading CPAP machines, Philips Respironics, SleePath includes a CARDIO SLEEP DASHBOARD which allows physicians to track multiple aspects of a patient’s sleep apnea status anytime and anyplace. The system monitors care pathway progress, diagnosis status and results, CPAP compliance, the number of days and hours on CPAP and residual sleep apnea. Data are presented in a user-friendly visual format that makes it easy to see progress or deviation toward specific treatment goals and changes in metrics over time.
“Itamar Medical is committed to innovating technologies that allow effective sleep apnea management to be readily integrated into paradigms for protecting and improving cardiovascular health,” said Gilad Glick, CEO of Itamar Medical. “Devices using our PAT™ technology and our Total Sleep Solutions service are rapidly becoming important tools for improving the care of patients living with or at risk for a variety of cardiovascular disorders. SleePath provides cardiologists and electrophysiologists with insights into CPAP adherence that enable them to work their patients to achieve optimal outcomes. Now physicians don’t need to lose sleep over their patients’ sleep apnea.”
Attendees at Heart Rhythm 2018 can learn more about SleePath and Itamar Medical’s other products and services by visiting Booth #765 at the conference. Additional information is also available at https://cardiosleepsolutions.com.
About Itamar Medical Ltd.
Itamar Medical is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory disorders with focus on the cardiology market. The Company's flagship products, which are based on its unique technology, are WatchPAT™, a home-use diagnostic device for sleep breathing disorders, and EndoPAT™, an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. Itamar Medical is a public company traded on the Tel Aviv Stock Exchange and is based in Caesarea, Israel.
Media Contact
Erich Sandoval
Lazar Partners Ltd.
Tel: +1 917-497-2867
Email: [email protected]
1 Philips CPAP device date, on file.
